A year ago I had written about the potential role of IL-33, a member of
the IL-1 family, in rheumatoid arthritis and experimental inflammatory
arthritis. Last year it had been shown, that serum IL33 levels are increased especially
in anti-CCP positive RA patients. W.D. Xu and colleagues concluded, that “the
role of the IL-33/ST2 axis in B-cell immunopathology in RA needs to be further
addressed.”
This year J.-J. Kim and colleagues presented the following study [AB0066]:
“Clinical usefulness of serum soluble ST2 in rheumatoid arthritis with anti-TNF-α therapy”. Conclusions: “The serum sST2 level was
increased in RA patients, and correlated with other inflammatory markers of
disease activity. Monitoring of serum sST2 levels may be a possible marker of
effectiveness to anti-TNF-α therapy for RA patients,
when this is supported by an extended study with more patients.”
So we see further use of IL-33/ST2 as a marker, but we don’t know more
about “the role of the IL-33/ST2 axis in B-cell immunopathology in RA”. There
were two more studies, one on Sjogren’s syndrome and one on Adult Onset Still’s
Disease.
Link:
Studies at EULAR 2014:
[THU0054] INTERLEUKIN-33/ST2 AXIS IN PRIMARY SJOGREN’S SYNDROME:
EXPRESSION IN SERUM AND SALIVARY GLAND, AND CLINICAL ASSOCIATION
S.M. Jung 1, J.Y. Kang1, H.K. Min 1, J.H. Koh 1, Y.S. Suh1, J.H. Lee 1,
J. Lee 1, J.Y. Lee 1, J.-M. Kim2, J.H. Ju 1, K.-S. Park 1, S.-H. Park 1, H.-Y.
Kim3
[THU0531] SERUM SOLUBLE ST2 LEVEL IN PATIENTS WITH ADULT-ONSET STILL’S
DISEASE: A POTENTIAL BIOMARKER OF DISEASE ACTIVITY
J.H. Park 1, J.-J. Kim 2, D.-H. Yoo 2
[AB0066] CLINICAL USEFULNESS OF SERUM SOLUBLE ST2 IN RHEUMATOID
ARTHRITIS WITH ANTI-TNF-α THERAPY
J.-J. Kim, J.-I. Choi, Y.-B. Joo, D.-H. Yoo
No comments:
Post a Comment